Device-maker SPR Therapeutics raised $37 million in a Series D funding round led by Revelation Partners with participation from River Cities Capital and Mutual Capital Partners.
SPR plans to use the cash to speed the commercial use of its pain-relief device, the SPRINT Peripheral Nerve Stimulation System, fund clinical studies and invest in new technology.
“This additional funding will allow us...